Advertisement
Advertisement
AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock
11.89
USDSponsored
+0.08
+0.68%
May 20, 09:36 UTC -4
Open
AMRX Earnings Reports
Positive Surprise Ratio
AMRX beat 28 of 42 last estimates.
67%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$772.37M
/$0.23
Implied change from Q1 26 (Revenue/ EPS)
+6.90%
/-14.81%
Implied change from Q2 25 (Revenue/ EPS)
+6.61%
/-8.00%
Amneal Pharmaceuticals, Inc. Class A Common Stock earnings per share and revenue
On Apr 22, 2026, AMRX reported earnings of 0.27 USD per share (EPS) for Q1 26, beating the estimate of 0.17 USD, resulting in a 55.71% surprise. Revenue reached 722.52 million, compared to an expected 729.58 million, with a -0.97% difference. The market reacted with a -1.54% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of 0.23 USD, with revenue projected to reach 772.37 million USD, implying an decrease of -14.81% EPS, and increase of 6.90% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ARS Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.61
Surprise
-13.81%
Galectin Therapeutics Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.08
Surprise
-30.72%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
$0.29
Actual
-$0.04
Surprise
-113.64%
Incannex Healthcare Limited - ADR
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.94
Actual
-$11.22
Surprise
-1088.38%
Marker Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.44%
PLUS THERAPEUTICS, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.89
Actual
-$1.05
Surprise
-16.98%
VYNE Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.08
Surprise
+56.43%
Scienture Holdings, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.08
Surprise
+64.35%
Wellgistics Health, Inc. Common Stock
Report Date
May 19, 2026 For Q1 26
Estimate
-Actual
-$0.07
Surprise
-
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.77
Actual
-$1.28
Surprise
-65.12%
FAQ
What were Amneal Pharmaceuticals, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Amneal Pharmaceuticals, Inc. Class A Common Stock reported EPS of $0.27, beating estimates by 55.71%, and revenue of $722.52M, -0.97% below expectations.
How did the market react to Amneal Pharmaceuticals, Inc. Class A Common Stock's Q1 2026 earnings?
The stock price moved down -1.54%, changed from $13.02 before the earnings release to $12.82 the day after.
When is Amneal Pharmaceuticals, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Amneal Pharmaceuticals, Inc. Class A Common Stock's next earnings report?
Based on 6
analysts, Amneal Pharmaceuticals, Inc. Class A Common Stock is expected to report EPS of $0.23 and revenue of $772.37M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement